Business
Emboline, Inc. Secures $20 Million in Growth Capital from Trinity Capital Inc. to Support Commercialization of the Emboliner® Embolic Protection System to Minimize Stroke Risk From TAVR
Emboline, Inc., a privately held medical technology company focused on reducing stroke and ischemic damage during structural heart procedures such as transcatheter aortic valve replacement (TAVR), today announced it has closed $20 Million in growth capital from Trinity Capital, a leading international alternative asset manager.
About this update from Trinity Capital Inc.
[{"type":"text","content":"SANTA CRUZ, Calif., March 11, 2026 /PRNewswire/ -- Emboline, Inc., a privately held medical technology company focused on reducing stroke and ischemic damage during structural heart procedures such as transcatheter aortic valve replacement (TAVR), today announced it has closed $20 Million in growth capital from Trinity Capital, a leading international alternative asset manager.","length":380,"tagName":"p"},{"type":"image","alt":"Emboline, Inc. Logo (PRNewsfoto/Emboline, Inc.)","displaySize":"","headline":null,"caption":"Emboline, Inc. Logo (PRNewsfoto/Emboline, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":61,"url":"https://media.zenfs.com/en/prnewswire.com/ab0507560f79e454172094571fef9617"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GYMTSlWzJQNDv_USlteT.Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEwODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/ab0507560f79e454172094571fef9617","width":400,"height":61}},"href":"https://mma.prnewswire.com/media/678735/Emboline_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Emboline recently completed enrollment in the PROTECT H2H investigational device exemption (IDE) clinical trial (NCT05684146), a prospective randomized study evaluating the Emboliner® Embolic Protection System. The funding will support Emboline's upcoming commercial launch activities and continued development of its embolic protection technology platform.","length":361,"tagName":"p"},{"type":"text","content":"The Emboliner® Embolic Protection System is designed to provide full cerebral and systemic embolic protection by capturing and removing embolic debris released during transcatheter heart procedures. Emboline also holds an extensive intellectual property portfolio related to aortic embolic protection technologies, including full-body embolic filtration and aortic deflection approaches.","length":387,"tagName":"p"},{"type":"text","content":"Results from the completed IDE clinical study will be presented in a Late-Breaking Clinical Trial session on March 29, 2026, at the American College of Cardiology Annual Scientific Session in New Orleans, Louisiana.","length":215,"tagName":"p"},{"type":"text","content":""Emboline's embolic filtering technology is designed with the goal of giving interventional cardiologists greater confidence...